The concept of producing inventory without a clear distribution plan in ARTH's situation is problematic. First of all, a distribution partner may wish a 'private label', using their brand names. They may wish that neither the name AC5 nor ARCH Therapeutics appear on the labeling; ARTH won't know until they negotiate a deal. Secondly, inventory - including finished goods, WIP and and components - ties up working capital which seems to be in scare supply in this case. Thirdly, the shelf life period starts counting down once product has been produced, packaged and sterilized. I fully expect that Norchi is well aware of all of the above. Most likely, Norchi meant that ARTH would start to acquire components when he made his remarks.
Market Data 
Markets 
AI
